Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.

CPE-005 · Fibrosis risk

LV-FIB-05: Advanced fibrosis likely

Advanced fibrosis likely. Evaluates FIB-4 above 2.67, OR liver stiffness 12 kPa or above, OR ELF 9.8 or above, OR cirrhosis known.

Active rulePriority 2Liver engine v1.0.0

Condition

  • FIB-4 above 2.67, OR liver stiffness 12 kPa or above, OR ELF 9.8 or above, OR cirrhosis known

What it reports

  • High-risk fibrosis result: advanced fibrosis or cirrhosis is likely enough to need specialist evaluation

Diagnostic boundary

  • Confirmation of stage belongs to hepatology.

Evidence

  • EV-AASLD-2023Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.Supports: FIB-4 first for risk stratification; thresholds <1.3 and >2.67; elastography 8 and 12 kPa; ELF 7.7 and 9.8 ALT upper limits near 29–33 U/L (men) and 19–25 U/L (women) Cardiovascular risk is the leading cause of death in MASLD

Cases where this rule fires

Open a case to see this rule fire with real inputs, then change the values until it stops.

The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.

Contact Biod